深圳康源久远生物技术有限公司

Developing innovative bispecifc antibody therapeutics – the next generation of monoclonal antibody therapeutics, with increased efficacy, favored pharmacokinetics and unique capability to recruit and redirect immune effector cells to kill the cancer cells for cancer immunotherapy.